Developer docs
API playgroundTry for free, no card

Search company profiles

Neotiv

Full company profile

uuid0002f2t

Namestring
Neotiv
Legal namestring
Neotiv GmbH
Websiteurl
neotiv.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Neotiv GmbH is a German digital health company developing the neotivCare® app, a CE-certified medical device that uses digital memory tests to detect early signs of cognitive impairment and Alzheimer's disease in at-risk individuals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMagdeburg, Germany
HQ citystring
Magdeburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
digital cognitive assessment, memory screening tools, Alzheimer's early detection, digital health medical devices, cognitive impairment monitoring
Industry2 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Health / Cognitive Diagnostics
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeSoftware
Software
Brand1 record
1neotivCare®
Description

A CE-certified medical device app that utilizes digital memory tests to identify cognitive impairment at an early stage for Alzheimer's detection.

european-biotechnology.com
Core offering1 text field

Neotiv develops and distributes the neotivCare® app, a CE-certified medical device that administers digital memory tests on a mobile platform to identify cognitive impairment at an early stage and support early Alzheimer's detection. The product targets individuals at risk of cognitive decline and is positioned as an accessible, non-invasive early screening tool for cognitive health.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1neotivCare® App
CategoryDigital health / cognitive diagnostics medical device
Description

A CE-certified medical device mobile application that administers digital memory tests to identify cognitive impairment at an early stage, enabling early Alzheimer's detection. Targeted at individuals at risk for cognitive decline and supporting healthcare providers in early cognitive screening.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Provides CANTAB, a computerized cognitive testing platform widely used in clinical trials and clinical practice. Most directly comparable to Neotiv in offering validated, digital memory and cognitive assessment tools targeting Alzheimer's and other CNS indications.

TypeDirect peer
Description

Commercializes computerized cognitive tests used in clinical trials and healthcare. Directly comparable to Neotiv as a digital cognitive assessment vendor serving both research and clinical customers in neurodegenerative disease.

TypeEmerging player
Description

Develops a digital biomarker platform for early Alzheimer's detection using smartphone-based cognitive tasks and AR. Closely aligned with Neotiv on mobile-first, digital memory testing for pre-symptomatic cognitive decline.

TypeEmerging player
Description

Offers a digital cognitive assessment platform (e.g., DCTclock) for early detection of Alzheimer's and other dementias, sold to clinicians and health systems. Comparable target use case to Neotiv's neotivCare®.

TypeEmerging player
Description

Combines digital cognitive tests with EEG and other biomarkers for CNS clinical trials and early dementia detection. Overlaps with Neotiv in digital memory assessment for early-stage cognitive impairment.

TypeEmerging player
Description

Provides a digital cognitive assessment and care platform used by clinicians to detect and manage cognitive impairment. Similar product positioning to Neotiv for cognitive screening and monitoring.

TypeEmerging player
Description

Mobile digital cognitive assessment platform aimed at early detection of dementia and other conditions. Comparable in deploying app-based cognitive testing for screening and monitoring.

TypeOthers
Description

Provides tau PET imaging ligands used in Alzheimer's research and clinical trials. Adjacent rather than competitive — useful as a complementary diagnostic partner to Neotiv's digital cognitive tests.

TypeOthers
Description

Major Alzheimer's therapeutics company (e.g., aducanumab) with active interest in digital screening tools for patient identification. Not a direct competitor, but a plausible partner or customer for Neotiv in trial recruitment and pre-screening.

10Eisai
TypeOthers
Description

Developer of lecanemab and other Alzheimer's therapies. Comparable as an adjacent ecosystem participant rather than a competitor; relevant for Neotiv as a potential partner integrating digital screening into treatment pathways.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neotiv

Digital Health / Cognitive Diagnosticsneotiv.com

Neotiv GmbH is a German digital health company developing the neotivCare® app, a CE-certified medical device that uses digital memory tests to detect early signs of cognitive impairment and Alzheimer's disease in at-risk individuals.

Neotiv firmographics

Firmographics
Name
Neotiv
Legal name
Neotiv GmbH
Website
https://neotiv.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Neotiv GmbH is a German digital health company developing the neotivCare® app, a CE-certified medical device that uses digital memory tests to detect early signs of cognitive impairment and Alzheimer's disease in at-risk individuals.
Ownership category
akta.pro rank

Neotiv industry classification

Industry
Product category
Digital Health / Cognitive Diagnostics
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care

Keywords

  • Digital cognitive assessment
  • Memory screening tools
  • Alzheimer's early detection
  • Digital health medical devices
  • Cognitive impairment monitoring

Where Neotiv is headquartered

Location

Headquarters

HQ city
Magdeburg
HQ country
Germany
HQ region
Europe

Markets served

Neotiv business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Neotiv product offering

Product offering

Core offering

Neotiv develops and distributes the neotivCare® app, a CE-certified medical device that administers digital memory tests on a mobile platform to identify cognitive impairment at an early stage and support early Alzheimer's detection. The product targets individuals at risk of cognitive decline and is positioned as an accessible, non-invasive early screening tool for cognitive health.

Differentiator

Problem solved

Functional benefit

Brands

  • neotivCare®: A CE-certified medical device app that utilizes digital memory tests to identify cognitive impairment at an early stage for Alzheimer's detection.

Products and services

  • neotivCare® App A CE-certified medical device mobile application that administers digital memory tests to identify cognitive impairment at an early stage, enabling early Alzheimer's detection. Targeted at individuals at risk for cognitive decline and supporting healthcare providers in early cognitive screening.

Companies that use Neotiv

Customer profile

Segments1 record

Ideal customer profiles1 record

Neotiv technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Neotiv partnerships and signals

Strategic signal

Scale indicators1 record

Neotiv competitors and assessment

Company assessment

Direct peers

  • Cambridge Cognition: Provides CANTAB, a computerized cognitive testing platform widely used in clinical trials and clinical practice. Most directly comparable to Neotiv in offering validated, digital memory and cognitive assessment tools targeting Alzheimer's and other CNS indications.
  • Cogstate: Commercializes computerized cognitive tests used in clinical trials and healthcare. Directly comparable to Neotiv as a digital cognitive assessment vendor serving both research and clinical customers in neurodegenerative disease.

Emerging players

  • Altoida: Develops a digital biomarker platform for early Alzheimer's detection using smartphone-based cognitive tasks and AR. Closely aligned with Neotiv on mobile-first, digital memory testing for pre-symptomatic cognitive decline.
  • Linus Health: Offers a digital cognitive assessment platform (e.g., DCTclock) for early detection of Alzheimer's and other dementias, sold to clinicians and health systems. Comparable target use case to Neotiv's neotivCare®.
  • Cumulus Neuroscience: Combines digital cognitive tests with EEG and other biomarkers for CNS clinical trials and early dementia detection. Overlaps with Neotiv in digital memory assessment for early-stage cognitive impairment.
  • BrainCheck: Provides a digital cognitive assessment and care platform used by clinicians to detect and manage cognitive impairment. Similar product positioning to Neotiv for cognitive screening and monitoring.
  • Savonix: Mobile digital cognitive assessment platform aimed at early detection of dementia and other conditions. Comparable in deploying app-based cognitive testing for screening and monitoring.

Others

  • Cerveau Technologies: Provides tau PET imaging ligands used in Alzheimer's research and clinical trials. Adjacent rather than competitive — useful as a complementary diagnostic partner to Neotiv's digital cognitive tests.
  • Biogen: Major Alzheimer's therapeutics company (e.g., aducanumab) with active interest in digital screening tools for patient identification. Not a direct competitor, but a plausible partner or customer for Neotiv in trial recruitment and pre-screening.
  • Eisai: Developer of lecanemab and other Alzheimer's therapies. Comparable as an adjacent ecosystem participant rather than a competitor; relevant for Neotiv as a potential partner integrating digital screening into treatment pathways.

Market position

Customer concentration

Neotiv compliance and trust

Trust signal

Compliance1 record

Neotiv financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neotiv leadership team

Management profile

Number of profiles

Profiles5 records

Neotiv funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neotiv M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neotiv

What does Neotiv do?

Neotiv develops and distributes the neotivCare® app, a CE-certified medical device that administers digital memory tests on a mobile platform to identify cognitive impairment at an early stage and support early Alzheimer's detection. The product targets individuals at risk of cognitive decline and is positioned as an accessible, non-invasive early screening tool for cognitive health.

Is Neotiv a public or private company?

Neotiv is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neotiv founded?

Neotiv was founded in 2017. It employs 11 to 50 people.

Where is Neotiv based?

Neotiv is headquartered in Magdeburg, Germany, in the Europe region.

Who are Neotiv's main competitors?

Direct peers on record are Cambridge Cognition and Cogstate. Emerging players are Altoida, Linus Health, Cumulus Neuroscience, BrainCheck and Savonix. Others are Cerveau Technologies, Biogen and Eisai.

Does Neotiv have an API?

No public API is recorded for Neotiv.

What industry is Neotiv in?

Neotiv's product category is Digital Health / Cognitive Diagnostics. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HSABAEAH, Cognitive Stimulation & Reminiscence Therapy (Non-Clinical). Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DzneIncreased Risk of Dementia? Study Evaluates Digital Memory Tests for Home UseThe German Center for Neurodegenerative Diseases (DZNE) is launching a study involving approximately 30 specialist practices in Germany to evaluate whether digital memory tests via the neotivCare app can aid in the early detection of mild cognitive impairment. The pharmaceutical company Lilly Deutschland GmbH is funding this healthcare study with 1.3 million euros over two years to assess the tool's utility in routine medical care. Results from the trial, which aims to include around 300 individuals, are expected by 2027.Tech.euAlzheimer's screening tool company Neotiv raises €10 millionNeotiv, a Germany-based Alzheimer's screening startup, raised €10 million in a series A round led by Capricorn Partners' Digital Growth Fund. The funds will support expansion of its neotivCare app, a CE class I medical device for early cognitive decline detection, and international growth. The company plans to target 32 million dementia patients globally.HighPre Series A neotivMagdeburg-based digital health company neotiv raised 10 million euros in a Pre-Series A financing round led by Capricorn Partners, High-Tech Gründerfonds, and bmp with IBG Fonds. The funds will be used to accelerate the nationwide supply of its neotivCare® app for early Alzheimer’s screening and drive international expansion. This investment supports the company's goal of improving patient care through scientifically validated digital diagnostic tools.StartbaseNeotiv raises ten million eurosNeotiv, a Magdeburg-based healthtech startup, has closed its Pre-Series A financing round, raising ten million euros from investors including Capricorn Partners and High-Tech Gründerfonds. The company intends to use the capital to accelerate the nationwide availability of its Neotivcare app, which utilizes digital memory tests to support customers with self-perceived memory problems and assist in diagnosing mild cognitive impairments.European BiotechnologyNeotiv GmbH closes €10m seed financingGermany-based Neotiv GmbH has closed a €10m pre-Series A funding round led by Capricorn Partners, High-Tech Gründerfonds, and bmp. The company plans to use the capital to launch its neotivCare® app for early Alzheimer’s detection internationally. This development follows increased attention on early diagnosis driven by positive Phase III trial results for Esai/Biogen’s lecanemab.FinSMEsNeotiv Secures Seed Funding from High-Tech GründerfondsNeotiv, a German digital health startup, secured undisclosed seed funding from High-Tech Gründerfonds. The company develops apps to measure early-stage Alzheimer's psychological effects, supporting patients, doctors, and drug developers. The app enables long-term memory monitoring and treatment tracking.